{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:33:52Z","timestamp":1774262032500,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T00:00:00Z","timestamp":1469404800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s40259-016-0188-z","type":"journal-article","created":{"date-parts":[[2016,7,25]],"date-time":"2016-07-25T06:47:09Z","timestamp":1469429229000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases"],"prefix":"10.1007","volume":"30","author":[{"given":"Celeste B.","family":"Burness","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean T.","family":"Duggan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"issue":"12","key":"188_CR1","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s40265-014-0258-9","volume":"74","author":"LJ Scott","year":"2014","unstructured":"Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs. 2014;74(12):1379\u2013410.","journal-title":"Drugs."},{"issue":"12","key":"188_CR2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1111\/jdv.13354","volume":"29","author":"A Nast","year":"2015","unstructured":"Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris\u2014Update 2015\u2014Short version\u2014EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol JEADV. 2015;29(12):2277\u201394.","journal-title":"J Eur Acad Dermatol Venereol JEADV."},{"issue":"6","key":"188_CR3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"188_CR4","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492\u2013509.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"188_CR5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499\u2013510.","journal-title":"Ann Rheum Dis"},{"key":"188_CR6","unstructured":"European Medicines Agency. Enbrel powder and solvent for solution for injection: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu . Accessed 4 Jul 2016."},{"issue":"2","key":"188_CR7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00296-014-3080-5","volume":"35","author":"VF Azevedo","year":"2015","unstructured":"Azevedo VF, Galli N, Kleinfelder A, et al. Etanercept biosimilars. Rheumatol Int. 2015;35(2):197\u2013209.","journal-title":"Rheumatol Int"},{"issue":"1","key":"188_CR8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198\u2013206.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"188_CR9","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","volume":"73","author":"P Putrik","year":"2014","unstructured":"Putrik P, Ramiro S, Kvien TK, et al. Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth? Ann Rheum Dis. 2014;73(11):2010\u201321.","journal-title":"Ann Rheum Dis"},{"key":"188_CR10","unstructured":"European Medicines Agency. Similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues: EMEA\/CHMP\/BMWP\/42832\/2005 Rev. 1. 2015. http:\/\/www.ema.europa.eu . Accessed 4 Jul 2016."},{"key":"188_CR11","unstructured":"European Medicines Agency. Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (EMA\/CHMP\/BWP\/247713\/2012). 2014. http:\/\/www.ema.europa.eu . Accessed 4 Jul 2016."},{"key":"188_CR12","doi-asserted-by":"publisher","unstructured":"Cho IH, Lee N, Song D, et al. Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept. mAbs. 2016. doi: 10.1080\/19420862.2016.1193659 .","DOI":"10.1080\/19420862.2016.1193659"},{"key":"188_CR13","unstructured":"European Medicines Agency. Benepali 50\u00a0mg solution for injection: summary of product characteristics. 2016. http:\/\/www.ema.europa.eu\/ . Accessed 4 Jul 2016."},{"key":"188_CR14","unstructured":"European Medicines Agency. European public assessment report (EPAR): Benepali (etanercept). 2016. http:\/\/www.ema.europa.eu . Accessed 4 Jul 2016."},{"key":"188_CR15","unstructured":"Samsung Bioepis. Samsung Bioepis, etanercept biosimilar, BRENZYS\u00ae (SB4) approved in South Korea [media release]. Sept 2015. http:\/\/www.samsungbioepis.com ."},{"key":"188_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12929","author":"YJ Lee","year":"2016","unstructured":"Lee YJ, Shin D, Kim Y, et al. A randomised phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel\u00ae) in healthy subjects. Br J Clin Pharmacol. 2016. doi: 10.1111\/bcp.12929 .","journal-title":"Br J Clin Pharmacol"},{"key":"188_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207588","author":"P Emery","year":"2015","unstructured":"Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015. doi: 10.1136\/annrheumdis-2015-207588 .","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"188_CR18","first-page":"2444","volume":"67","author":"J Vencovsky","year":"2015","unstructured":"Vencovsky J, Sylwestrzak A, Leszczynski P, et al. A phase III, randomized, double-blind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel\u00ae) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results) [abstract no. 2055 plus oral presentation]. Arthritis Rheumatol. 2015;67(Suppl 10):2444\u20136.","journal-title":"Arthritis Rheumatol."},{"key":"188_CR19","doi-asserted-by":"crossref","unstructured":"Emery P, Vencovsky J, Sylwestrzak A, et al. Long-term safety and efficacy of SB4 (etanercept biosimilar) in patients with rheumatoid arthritis: comparison between continuing SB4 and switching from etanercept reference product to SB4 [abstract no. THU0150]. In: EULAR 2016.","DOI":"10.1136\/annrheumdis-2016-eular.3137"},{"issue":"1","key":"188_CR20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1546-0096-11-35","volume":"11","author":"M Hooper","year":"2013","unstructured":"Hooper M, Wenkert D, Bitman B, et al. Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports. Pediatr Rheumatol Online J. 2013;11(1):35.","journal-title":"Pediatr Rheumatol Online J."},{"key":"188_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209665","author":"F Meacci","year":"2016","unstructured":"Meacci F, Manfredi M, Infantino M, et al. Anti etanercept and anti SB4 antibodies detection: impact of the assay method. Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2016-209665 .","journal-title":"Ann Rheum Dis"},{"key":"188_CR22","unstructured":"EvaluatePharma. World Preview 2015, Outlook to 2020. 2015. http:\/\/info.evaluategroup.com\/rs\/607-YGS-364\/images\/wp15.pdf . Accessed 4 Jul 2016."},{"issue":"3","key":"188_CR23","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s40259-014-0094-1","volume":"28","author":"K McKeage","year":"2014","unstructured":"McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014;28(3):313\u201321.","journal-title":"BioDrugs."},{"key":"188_CR24","unstructured":"European Medicines Agency. Summary of the risk management plan (RMP) for Benepali (etanercept). 2016. http:\/\/www.ema.europa.eu . Accessed 4 Jul 2016."},{"key":"188_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209502","author":"L Marshall","year":"2016","unstructured":"Marshall L, Hickling T, Bill D, et al. Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration. Ann Rheum Dis. 2016. doi: 10.1136\/annrheumdis-2016-209502 .","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"188_CR26","first-page":"A639","volume":"18","author":"L Ruff","year":"2015","unstructured":"Ruff L, Rezk MF, Uhlig T, et al. Budget impact analysis of an etanercept biosimilar for the treatment of all licensed etanercept indications for adults in Europe [abstract no. PMS33]. Value Health. 2015;18(7):A639.","journal-title":"Value Health."},{"key":"188_CR27","unstructured":"ABPI. ABPI position on biologic medicines, including biosimilar medicines. 2015. http:\/\/www.abpi.org.uk\/ . Accessed 4 Jul 2016."},{"issue":"1","key":"188_CR28","first-page":"60","volume":"39","author":"JE Fonseca","year":"2014","unstructured":"Fonseca JE, Goncalves J, Araujo F, et al. The Portuguese Society of Rheumatology position paper on the use of biosimilars. Acta Reumatologica Portuguesa. 2014;39(1):60\u201371.","journal-title":"Acta Reumatologica Portuguesa."},{"issue":"1","key":"188_CR29","first-page":"1","volume":"33","author":"F Atzeni","year":"2015","unstructured":"Atzeni F, Sebastiani M, Ricci C, et al. Position paper of Italian rheumatologists on the use of biosimilar drugs. Clin Exp Rheumatol. 2015;33(1):1\u20134.","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"188_CR30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.reuma.2015.03.009","volume":"11","author":"MA Abad Hernandez","year":"2015","unstructured":"Abad Hernandez MA, Andreu JL, Caracuel Ruiz MA, et al. Position paper from the Spanish Society of Rheumatology on biosimilar drugs. Reumatologia clinica. 2015;11(5):269\u201378.","journal-title":"Reumatologia clinica."},{"key":"188_CR31","unstructured":"British Society for Rheumatology. British Society for Rheumatology position statement on biosimilar medicines (February 2015). 2015. http:\/\/www.rheumatology.org.uk . Accessed 4 Jul 2016."}],"updated-by":[{"DOI":"10.1007\/s40259-016-0195-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,9,29]],"date-time":"2016-09-29T00:00:00Z","timestamp":1475107200000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-016-0188-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-016-0188-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-016-0188-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,11]],"date-time":"2019-09-11T13:19:45Z","timestamp":1568207985000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-016-0188-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,25]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["188"],"URL":"https:\/\/doi.org\/10.1007\/s40259-016-0188-z","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40259-016-0195-0","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,25]]}}}